Juan Buades Reinés

Juan Buades Reinés

Auto-generated profile, based on publicly available information

Juan Buades Reinés

Internal Medicine Department, Hospital Universitario Son Llàtzer, Palma de Mallorca, 07198 Palma, Spain

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 September 2015 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
OSOle B Suhr
Ole B Suhr
TCTeresa Coelho
Teresa Coelho
JBJuan Buades
Juan Buades
JPJean Pouget
Jean Pouget
ICIsabel Conceicao
Isabel Conceicao
DADavid Adams
David Adams
Transthyretin-mediated amyloidosis is an inherited, progressively debilitating disease caused by mutations in the transthyretin gene. This study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of patisiran (ALN-TTR02), a small interfering RNA encapsulated within lipid nanoparticles, in patients with transthyretin-mediated familial amyloid polyneuropathy (FAP). In this phase II study, patients with FAP were administered 2 intravenous infusions of patisiran at one of the following doses: 0.01 (n = 4), 0.05 (n = 3), 0.15 (n = 3), or 0.3 (n = 7) mg/kg every 4 weeks (Q4W), or 0.3 mg/kg (n = 12) every 3 weeks (Q3W). Of 29 patients in the intent-to-treat population, 26 completed the study. Administration of patisiran led to rapid, dose-dependent, and durable knockdown of transthyretin, with the maximum effect seen with patisiran 0.3 mg/kg; levels of mutant and wild-type transthyretin were reduced to a similar extent in Val30Met patients. A mean level of knockdown exceeding 85 % after the second dose, with maximum knockdown of 96 %, was observed for the Q3W dose. The most common treatment-related adverse event (AE) was mild-to-moderate infusion-related reactions in 10.3 % of patients. Four serious AEs (SAEs) were reported in 1 patient administered 0.3 mg/kg Q3W (urinary tract infection, sepsis, nausea, vomiting), and 1 patient administered 0.3 mg/kg Q4W had 1 SAE (extravasation-related cellulitis). Patisiran was generally well tolerated and resulted in significant dose-dependent knockdown of transthyretin protein in patients with FAP. Patisiran 0.3 mg/kg Q3W is currently in phase III development. NCT01617967 .

1 January 2014 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
JRJuan B Reinés
Juan B Reinés
TRTomás Ripoll-Vera
Tomás Ripoll-Vera
MMMercedes U Martín
Mercedes U Martín
HSHernán Serra
Hernán Serra
MCMa Margarita C Campins
Ma Margarita C Campins
MCManuel R Cruz
Manuel R Cruz
Transthyretin-associated Familial Amyloid Polyneuropathy (TTR-FAP) is an autosomal dominant disease caused by the deposition of abnormal transthyretin that results from a gene mutation. Although rare worldwide, there are descriptions of several endemic foci, such as in Majorca, Balearic Islands, Spain. We aimed at describing a contemporary series of TTR-FAP patients in Son Llàtzer Hospital in Majorca from an epidemiological point of view in order to report their main clinical and laboratory characteristics.

1 April 2000 in European Journal of Human Genetics
Verified
Journal Article
Closed access
PDF file
CDCecile Domingo
Cecile Domingo
ITIsabelle Touitou
Isabelle Touitou
ABAnne Bayou
Anne Bayou
SOSeza Ozen
Seza Ozen
CNCécile Notarnicola
Cécile Notarnicola
EBEldad Ben-Chetrit
Eldad Ben-Chetrit

7 December 2016 in Journal of the Peripheral Nervous System
Verified
Journal Article
Open access
PDF file
JBJuan Buades-Reinés
Juan Buades-Reinés
MRManuel Raya-Cruz
Manuel Raya-Cruz
CGCristina Gallego-Lezaún
Cristina Gallego-Lezaún
TRTomás Ripoll-Vera
Tomás Ripoll-Vera
MUMercedes Usón-Martín
Mercedes Usón-Martín
ECEugenia Cisneros-Barroso
Eugenia Cisneros-Barroso
The age of onset (AO) of hereditary ATTR amyloidosis (hATTR) is known to vary between populations, with differing characteristics reported according to AO in endemic/non‐endemic foci. This was a retrospective study of patients with early AO (<50 years) and late AO (≥50 years) hATTR at our center in Mallorca. Data were collected on patient demographics, clinical disease manifestation, and physical symptoms. A total of 95 patients were analyzed, with mean follow‐up of 9 years from diagnosis. The early AO group included 53 patients (33 male) and the late AO group included 42 patients (21 male). Neurologic involvement was the most common initial symptom, although it was significantly more frequent in the late AO vs. early AO group (p = 0.015). Autonomic involvement was observed in 26% of patients in the early AO group, but was rarely observed in the late AO group (5%). During follow up, cardiologic symptoms, renal involvement, and ophthalmologic symptoms were significantly more common in the late AO group (p < 0.05). This retrospective study demonstrates the variation in disease presentation and progression according to AO of hATTR at our Mallorcan center.

1 January 2017 in Medicina Clinica
Verified
Journal Article
Closed access
MRManuel Raya-Cruz
Manuel Raya-Cruz
JBJuan Buades-Reines
Juan Buades-Reines
CGCristina Gállego-Lezáun
Cristina Gállego-Lezáun
TRTomás Ripoll-Vera
Tomás Ripoll-Vera
MUMercedes Usón-Martín
Mercedes Usón-Martín
ECEugenia Cisneros-Barroso
Eugenia Cisneros-Barroso

13 December 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
ILInés Losada
Inés Losada
JGJuan Gonzalez-Moreno
Juan Gonzalez-Moreno
JRJuan Buades Reinés
Juan Buades Reinés
TSTeresa Sevilla
Teresa Sevilla
FVFernando Martinez Valle
Fernando Martinez Valle
FSFrancesca Setaro
Francesca Setaro
Background: Hereditary transthyretin amyloidosis (ATTRv) is an autosomal-dominant systemic disease, where amyloid fibrils accumulate especially in the peripheral and autonomic nervous systems and in the heart. The aim of the present work was to outline the follow-up and type of management received by asymptomatic carriers (ACs) and Coutinho stage 1 ATTRv patients in Spain. Methods: A cross-sectional, non-interventional study was conducted throughout seven experienced hospitals in Spain. A total of 86 ACs without neurological symptoms and 19 Coutinho stage 1 ATTRv patients diagnosed 12 months before their enrollment were included. Clinical and demographic data, red flags, and neurological and cardiological evaluations were gathered. In addition, site variables were collected from four centers to describe the clinical management of ATTRv. Results: ATTRv clinical management varied depending on the center setting but was primarily overseen by neurology and internal medicine, which were responsible for the holistic follow-up of ACs and patients. Routinely, neurologists, neurophysiologists, cardiologists, and internal medicine conducted the follow-up. Specialties involved in initial AC assessment were neurophysiologists and cardiologists in 100% of cases, neurologists (75%), internists and geneticists (50%), and ophthalmologists (25%). A review of the medical tests performed proved an exhaustive management of the study population. Stable patients were followed up every 6 months, while those under evolution were monitored every 3–6 months. The frequency of monitoring of ACs was annual, and carriers classified with doubtful disease onset were visited every 3–6 months. Conclusions: The EMPATIa study provides valuable insights into the management of ATTRv in a real-world clinical setting in highly experienced hospitals in Spain. It demonstrates that multidisciplinary practice and enhanced disease awareness may lead to a reduction in diagnostic delay.